Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
J Clin Endocrinol Metab. 2024 Oct 15;109(11):2979-2985. doi: 10.1210/clinem/dgae214.
Medullary thyroid cancer (MTC) often exhibits aggressive growth with distant organ metastasis, leading to poor survival.
The question of whether primary tumor resection (PTR) is beneficial for patients with metastatic MTC remains a subject of debate. In this study, we evaluated the prognostic significance of organ-specific metastases and the number of metastatic organs in these patients, and we also conducted an analysis to determine the therapeutic value of PTR in managing this rare malignancy.
Patients initially diagnosed with metastatic MTC were identified within the Surveillance, Epidemiology, and End Results database. Univariable and multivariable Cox proportional hazards regression models were performed to identify survival predictors. Survival outcomes were calculated using the Kaplan-Meier method and compared using the log-rank tests.
A total of 186 patients with metastatic MTC at initial diagnosis from 2010 to 2020 were included. Bone, lung, and liver were the most common metastatic organs. Patients with brain metastasis had significantly worse overall survival (P = .007) and cancer-specific survival (P = .0013). Among all patients, 105 (56.45%) underwent PTR, and this group showed reduced overall mortality and cancer-specific mortality (all P < .05). When analyzing different metastatic patterns, PTR significantly lowered the risk of overall mortality and cancer-specific mortality for patients with bone, lung, liver, or distant lymph node involvement (all P < .05). Additionally, among patients with 1 or 2 metastases, those undergoing surgical resection were significantly associated with favorable overall survival (P = .008) and cancer-specific survival (P = .0247).
PTR may confer therapeutic benefits for carefully selected individuals with metastatic MTCs. To integrate these insights into clinical decision-making settings, it is imperative to undertake multicenter prospective studies in the future.
甲状腺髓样癌(MTC)常表现为侵袭性生长伴远处器官转移,导致预后不良。
原发肿瘤切除术(PTR)是否对转移性 MTC 患者有益,这一问题仍存在争议。本研究评估了此类患者的器官特异性转移和转移器官数量的预后意义,并分析了 PTR 对这种罕见恶性肿瘤的治疗价值。
从监测、流行病学和最终结果数据库中确定了最初诊断为转移性 MTC 的患者。采用单变量和多变量 Cox 比例风险回归模型来确定生存预测因素。使用 Kaplan-Meier 方法计算生存结局,并通过对数秩检验进行比较。
共纳入了 2010 年至 2020 年期间初诊时患有转移性 MTC 的 186 例患者。骨、肺和肝是最常见的转移器官。有脑转移的患者总生存率(P=.007)和癌症特异性生存率(P=.0013)显著更差。所有患者中,有 105 例(56.45%)接受了 PTR,该组的总死亡率和癌症特异性死亡率均降低(均 P <.05)。在分析不同的转移模式时,PTR 显著降低了有骨、肺、肝或远处淋巴结受累患者的总死亡率和癌症特异性死亡率(均 P <.05)。此外,在有 1 或 2 个转移灶的患者中,接受手术切除与总生存(P=.008)和癌症特异性生存(P=.0247)显著相关。
PTR 可能为精心挑选的转移性 MTC 患者带来治疗益处。为了将这些发现纳入临床决策制定环境,未来必须开展多中心前瞻性研究。